I'm no shares guru, so I just want to ask those on here that are so much more experienced and/or are even in the industry, if this is a reasonable assumption IF we get the final nod from the FDA for SB:
-Only $36m gross revenue per year from SB (simply 3 x times that of what Japan actually sold last year of Ecclock, because of population differential)
-$36m divided by 1.2B shares = $0.03 earnings per share.
- Multiply that by a PE Ratio of 10 to 15 times
-And we should be looking at a stock worth 30c to 45c.
Have I got that right?
And of course if we actually earn closer to $150m/yr, then we'd be looking at a stock vale of $1.20 to $1.90. No?
Not taking into account anything other than SB sales.
BOT - Anything but charting, page-3772
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $617.9M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 34.3¢ | 32.5¢ | $1.814M | 5.424M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 489055 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 340303 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |